Identification of an Immune Gene-Based Cisplatin Response Model and CD27 as a Therapeutic Target against Cisplatin Resistance for Ovarian Cancer

<div>The immune microenvironment of cisplatin-resistant and cisplatin-sensitive OV groups. (a) The immune cell scores of cisplatin-resistant and cisplatin-sensitive groups. The dendrogram showed the hierarchical clustering results of cisplatin-resistant and cisplatin-sensitive groups. (b) Differentially expressed immune genes between cisplatin-resistant and cisplatin-sensitive groups. The red and blue points represented upregulated and downregulated genes, respectively. The texts indicated the symbols of nine Treg-related genes. (c) The expression profiles of nine Treg-related genes in cisplatin-resistant and cisplatin-sensitive groups.</div>

Journal of Immunology Research

fig1

Figure 1

Figure 1: Identification of an Immune Gene-Based Cisplatin Response Model and CD27 as a Therapeutic Target against Cisplatin Resistance for Ovarian Cancer 

Figure 1 | Identification of an Immune Gene-Based Cisplatin Response Model and CD27 as a Therapeutic Target against Cisplatin Resistance for Ovarian Cancer 